The U.S. Army Medical Research and Materiel Command (USAMRMC) at Fort Detrick is soliciting proposals which provide enhanced solutions to medical problems of importance to the military services.
The Broad Agency Announcement (BAA) supports research and development programs which play a vital role in the fulfillment of the objectives established by the USAMRMC, and is specifically geared for extramural basic and applied research not related to development of a specific system or hardware procurement.
Research and development funded through this BAA is intended to benefit and inform both military and civilian medical practice and knowledge. Projects must be for scientific study and experimentation directed toward advancing the state-of-the-art or increasing knowledge or understanding.
Highlighted research areas of interest include:
- Development of novel treatments to reverse paralysis in nerve terminals exposed to botulinum neurotoxin (BoNT) serotypes A, B, E, or F
- Development of sensitive and specific immunologic, chemical, or biological assays for rapid and reliable diagnoses of acute diseases due to agents of potential biological threat
- Vaccines, anti-parasitic drugs, deployable field clinical diagnostics, prophylactics and novel therapeutics to treat multidrug-resistant organisms in combat wound infections
- Novel technologies and treatments for naturally occurring infectious diseases including norovirus and other viral diarrhea, Q fever (Coxiella burnetii), Crimean-Congo hemorrhagic fever, protozoal diarrhea, Rickettsiosis, Chikungunya virus, multidrug-resistant bacteria and fungi, and technologies that leverage current research efforts in malaria, dengue, bacterial diarrhea, and HIV
- Clinical studies with therapeutics for prevention of or treatment against multidrug-resistant bacteria, fungi, and emerging infectious disease threats (e.g., Chikungunya virus, MERS-CoV)
- Discovery, design, and development of anti-parasitic drugs
- Investigations of parasitic metabolism, structural biology, genomics, proteomics, and metabolomics directed toward the identification of potential novel molecular targets for intervention
- Vector control products, with primary emphasis on malaria, dengue, and scrub typhus
- Thermostable treatments and ruggedized material solutions for Combat Casualty Care, with emphasis on field treatment of hemorrhage, traumatic brain injury, spinal cord injury and organ damage.
- Viral, toxin, and bacterial studies for identification and characterization of organisms and toxins
- Vaccine development, with emphasis on protection from aerosolized agents, molecular approaches for development of vaccines, measurement of relevant cellular and humoral protective immune responses, and expression or production of protective antigens using recombinant technology
- Discovery of novel or unique biochemical elements or compounds with antiviral, antibacterial, or antitoxin activity against biological organisms
This BAA is continuously accepting proposals for a 12-month period, from October 1, 2015 through September 30, 2016. Submission of a pre-proposal is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP). If the USAMRMC is interested in receiving a full proposal, they will invitation the applicant to submit one via eBRAP.
Further details are available via Solicitation Number: W81XWH-16-R-BAA1.
